• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Akumin Provides Business Update and Announces CFO Transition

    8/12/22 5:56:00 PM ET
    $AKU
    $ELV
    $SGRY
    Medical Specialities
    Health Care
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email

    PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today.

    The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized transformation specialist to help implement the program. As a part of this transformation, the Company announced: (a) the termination of employment of its Chief Financial Officer, William Larkin, and the appointment of David Kretschmer, an experienced transformation finance executive who successfully completed other business transformations in the healthcare industry, as Interim Chief Financial Officer, effective today; and (b) the sale of certain accounts receivables by subsidiaries of the Company to a third-party buyer for a purchase price of approximately $30 million.

    Riadh Zine, Chairman and Chief Executive Officer of Akumin, commented: "Our transformation efforts to date have already resulted in significant efficiencies to our operations and show a positive momentum for further efficiencies, as discussed in our second quarter results.  I am very excited to welcome David as our new Interim Chief Financial Officer. We are thrilled to have his expertise complement our team as we successfully execute our transformation program. On behalf of the board of directors of Akumin, I would also like to thank Bill for his contributions to the Company and wish him the very best in his next endeavors."

    Mr. Zine continued: "The sale of certain accounts receivables has significantly improved the liquidity of our Company by an immediate cash infusion of approximately $30 million and a reduction in our days sales outstanding of our accounts receivables. Our cash position at the end of the second quarter of 2022 pro forma this sale would have been approximately $69 million. In addition, any future sale of similar accounts receivables in the normal course of business would not be expected to have any material impact on our revenues."

    Before joining the Company, Mr. Kretschmer previously worked for Surgery Partners, Inc. (NASDAQ:SGRY), a multi-specialty ambulatory surgical center company with $2.5 billion of revenues, as interim CFO and executive vice president of strategy and transformation, and, prior to that, as senior vice president, treasurer and CIO for Anthem, Inc. renamed Elevance Health, Inc. (NASDAQ:ELV), a health insurance provider with more than $130 billion of revenues, and he was a key team member in the execution of the successful business transformation of each of these companies.

    About Akumin

    Akumin is a national leader in comprehensive outpatient radiology and oncology solutions and a partner of choice for U.S. hospitals, health systems and physician groups. Akumin provides fixed-site outpatient radiology and oncology services through a network of 234 owned and/or operated centers; as well as outpatient radiology and oncology solutions to approximately 1,000 hospitals and health systems across 48 states. Akumin combines clinical and operational expertise with the latest advances in technology and information systems to deliver patient-centered innovation, service standardization and exceptional healthcare value to its patients and partners. For more information, visit www.akumin.com.

    Forward-Looking Information

    Certain information in this press release constitutes forward-looking information or forward-looking statements. In some cases, but not necessarily in all cases, such statements or information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

    Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the factors described in greater detail in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended June 30, 2022, filed with the SEC on August 9, 2022,  which is available at www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

    Cision View original content:https://www.prnewswire.com/news-releases/akumin-provides-business-update-and-announces-cfo-transition-301605278.html

    SOURCE Akumin Inc.

    Get the next $AKU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKU
    $ELV
    $SGRY

    CompanyDatePrice TargetRatingAnalyst
    Elevance Health Inc.
    $ELV
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    Elevance Health Inc.
    $ELV
    3/17/2025$450.00Hold → Buy
    Argus
    Elevance Health Inc.
    $ELV
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    Surgery Partners Inc.
    $SGRY
    12/16/2024$30.00Buy
    BofA Securities
    Elevance Health Inc.
    $ELV
    10/18/2024Buy → Hold
    Argus
    Surgery Partners Inc.
    $SGRY
    10/14/2024$38.00Buy
    UBS
    Surgery Partners Inc.
    $SGRY
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    Elevance Health Inc.
    $ELV
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $AKU
    $ELV
    $SGRY
    SEC Filings

    See more
    • Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/28/25 6:31:33 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/14/25 5:27:34 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surgery Partners Inc.

      SCHEDULE 13G/A - Surgery Partners, Inc. (0001638833) (Subject)

      5/14/25 12:24:27 PM ET
      $SGRY
      Hospital/Nursing Management
      Health Care

    $AKU
    $ELV
    $SGRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surgery Partners, Inc. Announces First Quarter 2025 Results; Reaffirms Full Year 2025 Guidance

      BRENTWOOD, Tenn., May 12, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights(All comparisons are year-over-year unless otherwise noted) Revenue increased 8.2% for the first quarter Same-facility revenues increased 5.2% for the first quarterSame-facility cases increased 6.5% for the first quarter Net loss attributable to Surgery Partners, Inc. was $37.7 million for the first quarter Adjusted EBITDA increased 6.6% to $103.9 million for the first quarter 2025 Guidan

      5/12/25 7:30:00 AM ET
      $SGRY
      Hospital/Nursing Management
      Health Care
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Surgery Partners, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Details

      BRENTWOOD, Tenn., April 18, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2025 results before the market opens on Monday, May 12, 2025, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)Replay (available 3 hours after the call and available until May 26, 2025): 1-844-512-2921 (domestic), 1-412-317-6671 (international)Passcode for the live call and the replay: 13752904 Interested investor

      4/18/25 2:09:12 PM ET
      $SGRY
      Hospital/Nursing Management
      Health Care

    $AKU
    $ELV
    $SGRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Strable-Soethout Deanna D was granted 601 shares, increasing direct ownership by 58% to 1,646 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:19:25 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Schneider Ryan M. was granted 601 shares, increasing direct ownership by 10% to 6,600 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:55 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Peru Ramiro G was granted 601 shares, increasing direct ownership by 7% to 9,345 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:24 PM ET
      $ELV
      Medical Specialities
      Health Care

    $AKU
    $ELV
    $SGRY
    Leadership Updates

    Live Leadership Updates

    See more
    • Surgery Partners, Inc. Names Laura L. Forese, MD to Board of Directors

      BRENTWOOD, Tenn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company") today announced that Dr. Laura L. Forese has been appointed to serve as an independent director on its Board of Directors. Dr. Forese's appointment, which is effective January 10, 2025, will increase the size of Surgery Partners' Board to eleven members. Dr. Forese joins the Surgery Partners Board with extensive healthcare experience. Her career in healthcare administration spans over 40 years, most recently serving as an executive vice president and chief operating officer for New York-Presbyterian, one of the nation's most comprehensive, integrated academic heal

      1/13/25 5:00:24 PM ET
      $SGRY
      Hospital/Nursing Management
      Health Care
    • Elevance Health Appoints Nathan Rich Vice President, Investor Relations

      Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

      11/4/24 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

      Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

      10/30/24 12:55:00 PM ET
      $ELV
      Medical Specialities
      Health Care

    $AKU
    $ELV
    $SGRY
    Financials

    Live finance-specific insights

    See more
    • Surgery Partners, Inc. Announces First Quarter 2025 Results; Reaffirms Full Year 2025 Guidance

      BRENTWOOD, Tenn., May 12, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights(All comparisons are year-over-year unless otherwise noted) Revenue increased 8.2% for the first quarter Same-facility revenues increased 5.2% for the first quarterSame-facility cases increased 6.5% for the first quarter Net loss attributable to Surgery Partners, Inc. was $37.7 million for the first quarter Adjusted EBITDA increased 6.6% to $103.9 million for the first quarter 2025 Guidan

      5/12/25 7:30:00 AM ET
      $SGRY
      Hospital/Nursing Management
      Health Care
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Surgery Partners, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Details

      BRENTWOOD, Tenn., April 18, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2025 results before the market opens on Monday, May 12, 2025, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)Replay (available 3 hours after the call and available until May 26, 2025): 1-844-512-2921 (domestic), 1-412-317-6671 (international)Passcode for the live call and the replay: 13752904 Interested investor

      4/18/25 2:09:12 PM ET
      $SGRY
      Hospital/Nursing Management
      Health Care

    $AKU
    $ELV
    $SGRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

      SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      11/14/24 1:22:35 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surgery Partners Inc.

      SC 13G/A - Surgery Partners, Inc. (0001638833) (Subject)

      11/8/24 10:46:38 AM ET
      $SGRY
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G filed by Surgery Partners Inc.

      SC 13G - Surgery Partners, Inc. (0001638833) (Subject)

      10/24/24 2:02:10 PM ET
      $SGRY
      Hospital/Nursing Management
      Health Care

    $AKU
    $ELV
    $SGRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevance Health downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

      4/15/25 9:24:40 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health upgraded by Argus with a new price target

      Argus upgraded Elevance Health from Hold to Buy and set a new price target of $450.00

      3/17/25 8:22:06 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Stephens with a new price target

      Stephens downgraded Elevance Health from Overweight to Equal-Weight and set a new price target of $440.00 from $520.00 previously

      1/22/25 7:37:04 AM ET
      $ELV
      Medical Specialities
      Health Care